-
公开(公告)号:US20170362234A1
公开(公告)日:2017-12-21
申请号:US15527581
申请日:2015-11-19
发明人: James Lamond ELLIS , Karen Anderson EVANS , Ryan Michael FOX , William Henry MILLER , Mark Andrew SEEFELD
IPC分类号: C07D471/18 , C07D519/00 , A61K31/5517
CPC分类号: C07D471/18 , A61K31/551 , A61K31/5517 , C07D487/18 , C07D519/00
摘要: The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.
-
公开(公告)号:US20170015666A1
公开(公告)日:2017-01-19
申请号:US15123769
申请日:2015-03-06
IPC分类号: C07D471/14
CPC分类号: C07D471/14
摘要: This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
摘要翻译: 本发明涉及式(I)的新化合物,其为Zeste同系物2(EZH2)的增效剂的抑制剂,含有它们的药物组合物,其制备方法及其在治疗癌症中的用途。 (一世)
-
公开(公告)号:US20180319810A1
公开(公告)日:2018-11-08
申请号:US15527941
申请日:2015-11-19
发明人: James Lamond ELLIS , Karen Anderson EVANS , Ryan Michaael FOX , William Henry MILLER , Mark Andrew SEEFELD
IPC分类号: C07D487/18 , A61K31/551 , A61K31/4995
CPC分类号: C07D487/18 , A61K31/4995 , A61K31/551 , A61K31/5517 , C07D471/18 , C07D519/00
摘要: The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.
-
公开(公告)号:US20190048016A1
公开(公告)日:2019-02-14
申请号:US15527851
申请日:2015-11-19
发明人: James Lamond ELLIS , Karen Anderson EVANS , Ryan Michael FOX , William Henry MILLER , Mark Andrew SEEFELD
IPC分类号: C07D487/18 , C07D519/00 , A61P25/28 , A61P3/10 , A61P9/00
摘要: The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.
-
公开(公告)号:US20170355705A1
公开(公告)日:2017-12-14
申请号:US15527440
申请日:2015-11-19
发明人: James Lamond ELLIS , Karen Anderson EVANS , Ryan Michael FOX , William Henry MILLER , Mark Andrew SEEFELD
IPC分类号: C07D487/18 , C07D471/18 , A61K31/551
CPC分类号: C07D487/18 , A61K31/4995 , A61K31/551 , A61K31/5517 , A61P3/10 , A61P9/00 , A61P25/28 , C07D471/18 , C07D519/00
摘要: The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and for use in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.
-
公开(公告)号:US20170029412A1
公开(公告)日:2017-02-02
申请号:US15292200
申请日:2016-10-13
发明人: Charles William BLACKLEDGE, JR. , Joelle Lorraine BURGESS , Neil W. JOHNSON , Jiri KASPAREC , Steven David KNIGHT , Louis V. LaFRANCE, III , Juan I. LUENGO , William Henry MILLER , Kenneth Allen NEWLANDER , Stuart Paul ROMERIL , Mark SCHULZ , Dai-Shi SU , Xinrong TIAN
IPC分类号: C07D409/14 , C07D409/06 , C07D405/14 , C07D409/12 , C07D401/12
CPC分类号: C07D409/14 , C07D401/12 , C07D403/12 , C07D405/14 , C07D409/06 , C07D409/12 , C07D413/14
摘要: This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
摘要翻译: 本发明涉及式(I)的新化合物,其为Zeste同系物2(EZH2)的增效剂的抑制剂,含有它们的药物组合物,其制备方法及其在治疗癌症中的用途。
-
公开(公告)号:US20160102083A1
公开(公告)日:2016-04-14
申请号:US14787866
申请日:2014-04-25
发明人: Charles William BLACKLEDGE, JR. , Joelle Lorraine BURGESS , Neil W. JOHNSON , Jiri KASPAREC , Steven David KNIGHT , Louis V. LaFRANCE, III , Juan I. LUENGO , William Henry MILLER , Kenneth Allen NEWLANDER , Stuart Paul ROMERIL , Mark SCHULZ , Dai-Shi SU , Xinrong TIAN
IPC分类号: C07D409/14 , C07D403/12 , C07D405/14 , C07D409/12
CPC分类号: C07D409/14 , C07D401/12 , C07D403/12 , C07D405/14 , C07D409/06 , C07D409/12 , C07D413/14
摘要: This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
-
-
-
-
-
-